Brooks Andrews joined EW in 2013 as an Associate, was promoted to Vice President in 2014 and to Principal in 2017.
Mr. Andrews has played a key role on the Board of Directors of EW growth equity portfolio companies AxoGen, BreatheAmerica, Cota, EyePoint Pharmaceuticals, Metabolon, and Xenex and formerly, ProteinSimple.
Prior to joining EW, Mr. Andrews worked at Friedman Fleischer & Lowe (“FFL”), a growth-oriented private equity firm based in San Francisco. At FFL, he worked on several healthcare services investments ranging from IT to practice management to urgent care. Prior to FFL, Mr. Andrews worked at Barclay’s Capital in the firm’s investment banking division, focusing on financings, mergers and acquisitions in the communications and media industries.
Mr. Andrews received Bachelor of Business Administration degrees in Economics and Finance and a Master of Arts degree in Economics from the University of Georgia, and a Master of Business Administration degree from Stanford University.